🚨 Big milestone in MASLD/MASH!
We now have two FDA-approved drugs:
🔸 Resmetirom (oral, THR-β agonist)
🔹 Semaglutide (weekly SC, GLP-1 RA)
I made this simple side-by-side comparison 👇
Resmetirom (thyroid hormone receptor beta-selective agonist) has made 🌊 waves 🌊 as the 🥇FDA-approved treatment for MASH with fibrosis.
Read @RichieManikat 's summary of this seminal @NEJM trial ⏬
#livertwitter#GITwitter#MedEd#FOAMed
https://t.co/HnEkBU4G2q
A new emerging option to potentially treat #MASH.
Read here 👇🏻
https://t.co/pEyGNl74ug
📌 Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis.
#GITwitter#LiverTwitter#MedEd
Thank you Dallas, for a great year. Had an amazing year training at UTSW, learning from amazing and brilliant teachers, and colleagues.
Now starting a new journey, becoming an attending 🇵🇷
We are thrilled to have Dr. Lindsay Meurer @linds_md join our transplant hepatology team later this year! Dr. Meurer is a @YaleDigestive alumnus and completing her tx liver fellowship at @UTSWGI .We look forward to her contributions in providing exceptional care to our patients!